Document Classification

Section Type: RESULTS

Text: As compared with placebo, rimonabant at a dose of 20 mg was associated with a significant (P < 0. 001) mean weight loss (repeated-measures method, -6. 7 + / -0. 5 kg, and last-observation-carried-forward analyses, -5. 4 + / -0. 4 kg), reduction in waist circumference (repeated-measures method, -5. 8 + / -0. 5 cm, and last-observation-carried-forward analyses, -4. 7 + / -0. 5 cm), increase in HDL cholesterol (repeated-measures method, +10. 0 + / -1. 6 percent, and last-observation-carried-forward analyses, +8. 1 + / -1. 5 percent), and reduction in triglycerides (repeated-measures method, -13. 0 + / -3. 5 percent, and last-observation-carried-forward analyses, -12. 4 + / -3. 2 percent).